Shorter Smoking History Tied to Lower Risk of Death in NSCLC Patients
A shorter smoking history is associated with a lower risk of death among patients with non-small cell lung cancer, a study suggests.
Diagnosis & Disease Information
Perioperative Toripalimab Improves EFS in NSCLC
Adding perioperative toripalimab to chemotherapy improves event-free survival in patients with resectable, stage III NSCLC, a phase 3 study suggests.
Extended Interval Dosing of ICIs Does Not Increase Immune-Related AEs
Switching from canonical to extended interval dosing of immune checkpoint inhibitors does not increase the incidence of immune-related adverse events, a study suggests.
Surufatinib Plus Toripalimab Deemed Potential First-Line Option for NSCLC
First-line treatment with surufatinib and toripalimab provided disease control in 100% of patients with advanced, PD-L1+ NSCLC.
Perioperative Durvalumab Improves Outcomes in Resectable NSCLC
Results from the AEGEAN trial suggest that adding perioperative durvalumab to neoadjuvant chemotherapy can improve outcomes in patients with resectable NSCLC.
Results Support Neoadjuvant Chemoimmunotherapy as Standard Care in NSCLC
Chemoimmunotherapy is superior to chemotherapy as neoadjuvant treatment for advanced, resectable non-small cell lung cancer, a meta-analysis suggests.
Taletrectinib Has “Meaningful Clinical Efficacy” in ROS1+ NSCLC
Taletrectinib can produce durable responses in patients with ROS1-positive non-small cell lung cancer, a phase 2 trial suggests.
Tusamitamab Ravtansine-Based Combinations Show Activity in NSCLC
Combination regimens including tusamitamab ravtansine have demonstrated activity in a phase 2 study of patients with CEACAM5+ non-small cell lung cancer.
Amivantamab Provides Long-Term Benefit in Heavily Pretreated NSCLC
Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.
Upfront Osimertinib Reduces Risk of Brain Progression in EGFR-Mutant NSCLC
Upfront osimertinib can reduce the risk of brain progression, when compared with gefitinib followed by osimertinib, in advanced EGFR-mutant NSCLC, a study suggests.
- Loading...
Loading...
Next post in ELCC 2023
Loading... 
Loading...